The GLOW stack combines GHK-Cu, TB-500, and BPC-157 into one protocol — targeting collagen synthesis, cell migration, and tissue repair simultaneously for skin, hair, and systemic regeneration.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
GLOW is the name given to a popular three-peptide combination protocol pairing GHK-Cu (copper peptide), TB-500 (Thymosin Beta-4), and BPC-157. Each of the three acts on different but complementary repair pathways, creating a synergistic effect greater than any single compound alone. GHK-Cu drives collagen and elastin synthesis and activates over 4,000 repair-associated genes. TB-500 promotes cell migration, angiogenesis, and anti-inflammatory resolution. BPC-157 accelerates tissue healing, gut repair, and vascular formation. Together, they create a comprehensive regenerative environment for skin, hair, connective tissue, and systemic recovery.
Mechanism of Action
The three compounds in the GLOW stack operate via distinct but reinforcing mechanisms. GHK-Cu activates the copper-dependent lysyl oxidase enzyme (essential for collagen crosslinking), upregulates antioxidant enzymes, and acts as a gene expression regulator — switching on repair programs across connective tissue, skin, and hair. TB-500 binds G-actin via its LKKTET domain, promoting cell migration and proliferation throughout injured or depleted tissue while reducing scarring via MMP modulation. BPC-157 stimulates VEGF, fibroblast growth factor, and nitric oxide systems to accelerate healing, reduce inflammation, and improve local blood supply. The combination addresses collagen quality (GHK-Cu), cellular scaffolding and migration (TB-500), and vascular + healing acceleration (BPC-157) simultaneously.
Key Research
Each component of the GLOW stack has an independent evidence base. GHK-Cu has been studied extensively at University of Washington by Loren Pickart — over 50 years of research on collagen synthesis, wound healing, and gene activation. TB-500 (Thymosin Beta-4) has Phase I/II human cardiac repair trial data (RegeneRx). BPC-157 has over 100 preclinical studies across multiple organ systems. The combination protocol itself is an experiential stack widely used in regenerative medicine contexts; formal trials of the combination have not been conducted.
GLOW Protocol: GHK-Cu 1–2 mg SC daily + BPC-157 250–500 mcg SC daily + TB-500 5 mg SC twice weekly for weeks 1–4, then 2.5 mg twice weekly for weeks 5–8. Can be supplemented with topical GHK-Cu (2–5% serum) applied to skin and scalp daily for direct skin and hair effects. All three can be drawn into the same syringe if reconstituted separately with BAC water (check compatibility at time of preparation). Cycle: 8 weeks on / 4 weeks off.
Full GLOW Skin and Hair Protocol: GHK-Cu 2 mg SC daily + BPC-157 300 mcg SC daily + TB-500 2.5 mg SC twice weekly, for 8 weeks. Add topical GHK-Cu 2% to scalp and face daily. Systemic Recovery Stack: same protocol as above for connective tissue, gut, and systemic repair applications — particularly effective post-surgery or during intense athletic training phases.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
The GLOW stack is generally well tolerated. Mild injection site redness, particularly from TB-500 injections, is the most commonly reported issue. A brief flu-like response during the first 2 weeks of TB-500 loading is common. BPC-157 may cause mild nausea in some individuals, particularly with oral dosing. GHK-Cu topical can cause mild skin redness initially — this typically resolves within the first few days of use. No significant hormonal or endocrine suppression is associated with any component of this stack.
Storage & Handling
Store each peptide separately in lyophilized form: GHK-Cu and BPC-157 at 2–8°C; TB-500 at -20°C for long-term or 2–8°C for up to 3 months. Once reconstituted, store all three at 2–8°C and use within 28 days. Do not mix and store as a combined vial long-term; draw from individual reconstituted vials per dose.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
